US 12,263,196 B2
Compositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
Seong Jun Yoon, Seoul (KR); Jee Soo Son, Seoul (KR); In Hwang Kim, Gyeonggi-do (KR); Hyoung Rok Paik, Incheon (KR); Eun Kyoung Oh, Gyeonggi-do (KR); Soo Youn Jun, Seoul (KR); and Sang Hyeon Kang, Seoul (KR)
Assigned to iNtRON Biotechnology, Inc., Gyeonggi-do (KR)
Filed by iNtRON Biotechnology, Inc., Gyeonggi-do (KR)
Filed on Oct. 19, 2023, as Appl. No. 18/490,521.
Application 18/490,521 is a continuation of application No. 17/227,284, filed on Apr. 10, 2021, abandoned.
Prior Publication US 2024/0041958 A1, Feb. 8, 2024
Int. Cl. A61K 35/76 (2015.01); A61P 31/04 (2006.01)
CPC A61K 35/76 (2013.01) [A61P 31/04 (2018.01)] 5 Claims
 
1. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis comprising:
administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-3 and a pharmaceutically acceptable carrier,
wherein the Siphoviridae bacteriophage Bac-FRP-3 is deposited in the Korean Collection for Type Culture (KCTC) under accession number KCTC 14401BP and has an ability to lyse the enterotoxigenic Bacteroides fragilis cells and the genome sequence as set forth in SEQ ID NO: 1,
wherein the Siphoviridae bacteriophage Bac-FRP-3 has a latent period of 10-100 minutes and a burst size of 1000-2100 plaque-forming units (PFU)/infected cell,
wherein the Siphoviridae bacteriophage Bac-FRP-3 has structural proteins in the size of approximately 25 kDa, 48 kDa, 68 kDa, 75 kDa, 117 kDa, and 245 kDa; and
wherein the composition has a concentration of Siphoviridae bacteriophage Bac-FRP-3 of 1× 104 pfu/ml to 1×1015 pfu/ml or 1×104 pfu/g to 1×1015 pfu/g.